Inhibikase Therapeutics (IKT) Common Equity (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Common Equity data on file, last reported at $167.6 million in Q1 2026.

• Common Equity for Q1 2026 came in at $167.6 million, up 95.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $167.6 million (up 95.52% YoY), and the FY2025 annual result was $172.9 million, up 82.26% from the prior year.
• Common Equity eased to $167.6 million in Q1 2026 per IKT's latest filing, from $172.9 million in the prior quarter.
• Over five years, Common Equity peaked at $172.9 million in Q4 2025 and troughed at -$530591.0 in Q3 2024.
• A 5-year average of $50.9 million and a median of $25.3 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity sank 103.53% in 2024, then surged 13839.08% in 2025.
• A 5-year view of Common Equity shows it stood at $21.0 million in 2022, then plunged by 47.81% to $11.0 million in 2023, then surged by 764.16% to $94.9 million in 2024, then surged by 82.26% to $172.9 million in 2025, then dropped by 3.06% to $167.6 million in 2026.
• Business Quant data shows IKT's Common Equity at $167.6 million in Q1 2026, $172.9 million in Q4 2025, and $72.9 million in Q3 2025.